Type-IIx
Well-known Member
This post is to answer a question sent by PM out in the open, as an illustration of the absence of rational drug use among even the most highly respected coaches to serve a given objective.
On the topic of combined DNP & slin: The two simply work at cross-purposes, as quoted. On this, I have in the past stated that:
[link]
You might see coaches (incorrectly) making claims that insulin can promote fat loss (they believe that exogenous insulin can support exercise-induced fat oxidation by blunting hyperglycemia). This is false, of course.
There is only a weak association between insulin sensitivity and maximal fat oxidation (in non-insulin users). This relates to the etiology of insulin resistance: normally (without exogenous insulin), as someone tends towards an obese phenotype, they will see systemic insulin resistance.
What one must understand is that the bodybuilding community equates "hyperglycemia" (blood glucose elevation) with "insulin resistance." This is false - because both high systemic (blood, plasma) glucose AND high systemic (blood, plasma) insulin reflect insulin resistance. That is, elevations to either, and especially to both, reflect insulin resistance.
To illustrate this point, HOMA-IR (a quantitative measure of insulin resistance) can be expressed by the formula fasting insulin * fasting glucose / 405 (or fasting serum insulin (μU/ml) * fasting plasma glucose [mmol/liter] / 22.5).
Exogenous supra-physiological insulin promotes insulin resistance (i.e., insulin toxicity) by several mechanisms, one is that with prolonged hyperinsulinemia, there is diminished autophosphorylation of the IR, and subsequent PI3K-AKT signaling is affected, thereby reducing GLUT-4 translocation in skeletal muscle.
Insulin is antilipolytic leading to attenuated fat availability and oxidation during exercise. Even fasting insulin levels (1.4 - 14.0 µIU/mL or 9.7 - 97.2 pmol/L) are sufficient to inactivate hormone sensitive lipase (HSL; the rate limiting step in mobilization of adipocytes) by ~50%.
The effect of insulin on lipid metabolism is as follows: (a) It decreases the rate of lipolysis in adipose tissue and hence lowers the plasma fatty acid level, (b) it stimulates fatty acid and triacylglycerol synthesis in tissues, although only to a minor extent in humans, (c) it increases the rate of very-low-density lipoprotein (VLDL) formation in the liver, (d) it increases the uptake of triglyceride from the blood into adipose tissue and muscle, (e) it decreases the rate of fatty acid oxidation in muscle and liver, (f) it increases the rate of cholesterol synthesis in liver.
On the topic of combined DNP & slin: The two simply work at cross-purposes, as quoted. On this, I have in the past stated that:
DNP certainly does block the anabolic effects of exogenous insulin as it sabotages the proton pump and interferes with Pi groups' uptake into the mitochondrial matrix, reducing substrates for ATPase.
Growth requires ATP. The practical purpose of exogenous insulin is growth. DNP works at cross-purposes with this (its purpose is fat loss and it's a very blunt instrument at that).
Insulin promotes skeletal muscle hypertrophy by increased muscle protein synthesis, b) reduced proteolysis, and c) transmembrane transport of AAs (non-BCAAs).
Only one of these (b) is particularly useful in skeletal muscle with the use of DNP for the preservation of muscle and strength. I'd suggest that androgens accomplish anticatabolism in skeletal muscle at low doses better than insulin.
[link]
You might see coaches (incorrectly) making claims that insulin can promote fat loss (they believe that exogenous insulin can support exercise-induced fat oxidation by blunting hyperglycemia). This is false, of course.
There is only a weak association between insulin sensitivity and maximal fat oxidation (in non-insulin users). This relates to the etiology of insulin resistance: normally (without exogenous insulin), as someone tends towards an obese phenotype, they will see systemic insulin resistance.
What one must understand is that the bodybuilding community equates "hyperglycemia" (blood glucose elevation) with "insulin resistance." This is false - because both high systemic (blood, plasma) glucose AND high systemic (blood, plasma) insulin reflect insulin resistance. That is, elevations to either, and especially to both, reflect insulin resistance.
To illustrate this point, HOMA-IR (a quantitative measure of insulin resistance) can be expressed by the formula fasting insulin * fasting glucose / 405 (or fasting serum insulin (μU/ml) * fasting plasma glucose [mmol/liter] / 22.5).
Exogenous supra-physiological insulin promotes insulin resistance (i.e., insulin toxicity) by several mechanisms, one is that with prolonged hyperinsulinemia, there is diminished autophosphorylation of the IR, and subsequent PI3K-AKT signaling is affected, thereby reducing GLUT-4 translocation in skeletal muscle.
Insulin is antilipolytic leading to attenuated fat availability and oxidation during exercise. Even fasting insulin levels (1.4 - 14.0 µIU/mL or 9.7 - 97.2 pmol/L) are sufficient to inactivate hormone sensitive lipase (HSL; the rate limiting step in mobilization of adipocytes) by ~50%.
The effect of insulin on lipid metabolism is as follows: (a) It decreases the rate of lipolysis in adipose tissue and hence lowers the plasma fatty acid level, (b) it stimulates fatty acid and triacylglycerol synthesis in tissues, although only to a minor extent in humans, (c) it increases the rate of very-low-density lipoprotein (VLDL) formation in the liver, (d) it increases the uptake of triglyceride from the blood into adipose tissue and muscle, (e) it decreases the rate of fatty acid oxidation in muscle and liver, (f) it increases the rate of cholesterol synthesis in liver.